Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662

Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer

(2013) D. de Wit et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

(2013) A.-J. M. de Graan et al.   CLINICAL CANCER RESEARCH

Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study

(2013) Jacqueline S. L. Kloth et al.   CLINICAL PHARMACOKINETICS

Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin

(2013) Laure Elens et al.   Pharmacogenetics and Genomics

CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin

(2013) Laure Elens et al.   PHARMACOGENOMICS

Quantification of Sunitinib and N-Desethyl Sunitinib in Human EDTA Plasma by Liquid Chromatography Coupled With Electrospray Ionization Tandem Mass Spectrometry

(2013) Nienke A. G. Lankheet et al.   THERAPEUTIC DRUG MONITORING

Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the “Missing Heritability” Problem

(2013) Kathrin Klein et al.   Frontiers in Genetics

Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies

(2012) Bo Gao et al.   JOURNAL OF CLINICAL ONCOLOGY

CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy

(2012) Laure Elens et al.   PHARMACOGENOMICS

Opposing regulation of cytochrome P450 expression by CAR and PXR in hypothyroid mice

(2012) Young Joo Park et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Population Analysis of Erlotinib in Adults and Children Reveals Pharmacokinetic Characteristics as the Main Factor Explaining Tolerance Particularities in Children

(2011) M. White-Koning et al.   CLINICAL CANCER RESEARCH

A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients

(2011) L. Elens et al.   CLINICAL CHEMISTRY

Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration

(2011) Seng Chuan Tang et al.   INTERNATIONAL JOURNAL OF CANCER

Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes

(2011) Chun-Fang Xu et al.   JOURNAL OF CLINICAL ONCOLOGY

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

(2011) B. I. Rini et al.   JNCI-Journal of the National Cancer Institute

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

(2011) Jesus Garcia-Donas et al.   LANCET ONCOLOGY

Genetic epidemiology of induced CYP3A4 activity

(2011) Nilufer Rahmioglu et al.   Pharmacogenetics and Genomics

The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients

(2011) Hylke de Jonge et al.   PHARMACOGENOMICS

Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib

(2010) A. A. M. van der Veldt et al.   CLINICAL CANCER RESEARCH

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

(2010) D Wang et al.   PHARMACOGENOMICS JOURNAL

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

(2009) Brett E. Houk et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients

(2009) B. E. Houk et al.   CLINICAL CANCER RESEARCH

Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity

(2009) Nielka P. van Erp et al.   JOURNAL OF CLINICAL ONCOLOGY

The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test

(2009) Beatrice Oneda et al.   Pharmacogenetics and Genomics

Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

(2008) Matthew H. Kulke et al.   JOURNAL OF CLINICAL ONCOLOGY